Revolution Pharmaceuticals因非小细胞肺癌资产而被列入摩根大通关注名单

2024-09-25 02:47

JPMorgan has added Revolution Medicines (NASDAQ:RVMD) to its Analyst Focus List in anticipation of several data releases in Q4 on non-small cell lung cancer candidate RMC-6236.
The firm has an outperform rating on the stock and a $54 price target (~27% upside based on Monday's close). It is also a Positive Catalyst Watch for Q4.
The data expected in Q4 includes follow-up phase 1 efficacy as monotherapy and safety data on a combination of RMC-6236 + Merck's (MRK) Keytruda (pembrolizumab).
Analyst Eric Joseph noted that he is looking for a greater than 35% objective response ratio and greater than eight months progression-free survival "as the bar to secure the 2L opportunity for RMC-6236 monotherapy."
He added that a treatment-emergent adverse event profile showing less than 15% Grade 3 and higher injury on liver function tests and less than 10% treatment discontinuation "could nevertheless be an added 5-30% tailwind for shares from unlocking front-line."

More on Revolution Medicines